inositol niacinate, 6556-11-2

Articles:

PubMed:	Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
PubMed:	Biotransformation and pharmacokinetics of inositol hexanicotinate in rats.
PubMed:	Niacin: chemical forms, bioavailability, and health effects.
PubMed:	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
PubMed:	Synthesis and antihyperlipidemic activity of acetylated derivative of ulvan from Ulva pertusa.
PubMed:	Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection.
PubMed:	Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
PubMed:	Purported benefits of inositol niacinate.
PubMed:	Antihyperlipidemic effects of different molecular weight sulfated polysaccharides from Ulva pertusa (Chlorophyta).
PubMed:	Inositol hexaniacinate.
PubMed:	The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial.
PubMed:	Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial.
PubMed:	A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
PubMed:	Inositol nicotinate in intermittent claudication.
PubMed:	Treatment of intermittent claudication with inositol nicotinate.
PubMed:	A double-blind placebo-controlled study of Hexopal in the treatment of intermittent claudication.
PubMed:	[Use of derivative resolution for the spectrophotometric analysis of drug mixtures. I. Determination of inositol hexanicotinate and bamethan sulfate in tablets].
PubMed:	[Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo].
PubMed:	Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
PubMed:	Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
PubMed:	Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
PubMed:	Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues.
PubMed:	[Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial].
PubMed:	A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
PubMed:	[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
PubMed:	[Clinical use of a thermal method for measuring peripheral blood flow according to A.M. Baptista (author's transl)].
PubMed:	[Inositol hexanicotinate and its cholesteropenic effect].
PubMed:	[Ulcers of the lower extremities. Treatment with inositol hexanicotinate].
PubMed:	[Ocular changes experimentally induced in guinea pigs treated with an association of kallikrein and meso-inositol hexanicotinate].
PubMed:	[On the fibrinolytic effect of the combination of kallikrein with meso-inositol hexanicotinate].
PubMed:	The use of Hexanicotol (inositol niacinate) in peripheral vascular disease.
PubMed:	[Research on skin temperature and internal temperature in subjects with obliterating arteriopathy. Action of the association of kallikrein and meso-inositol hexanicotinate].
PubMed:	[Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy].
PubMed:	[The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy].
PubMed:	[Effect of meso-inositol hexanicotinate on arteriosclerosis].
PubMed:	[FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE].
PubMed:	[APROPOS OF THE GASTROINTESTINAL ABSORPTION OF INOSITOL HEXANICOTINATE].
PubMed:	[PHARMACOLOGICAL EXPERIMENTS WITH A COMBINATION OF KALLIKREIN AND MESO-INOSITOL HEXANICOTINATE].
PubMed:	[CLINICAL TESTING OF MESO-INOSITOL-HEXANICOTINATE].
PubMed:	[CLINICAL TRIAL OF A NEW NICOTINIC ACID DERIVATIVE, MESO-INOSITOL-HEXANICOTINATE, IN NEUROPSYCHIATRY].
PubMed:	[INOSITOL HEXANICOTINATE IN THE THERAPY OF ULCUS CRURIS].
PubMed:	[Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate].
PubMed:	Inositol niacinate as a peripheral vasodilator.
PubMed:	[Apropos of the hypocholesterolemic effects of nicotinic acid. Experimental investigations of such a compound and of inositol hexanicotinate].
PubMed:	Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report.
PubMed:	Speripheral vascular disease in general practice. Some experiences with meso-inositol-hexanicotinate.